Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development.
PMID: 32925358
2020
Journal of acquired immune deficiency syndromes (1999)
Table: K65R
Prevalence and characteristics of HIV drug resistance among antiretroviral treatment (ART) experienced adolescents and young adults living with HIV in Ndola, Zambia.
Abstract: The mutation M184V which confers resistance to NRTI drugs of lamivudine (3TC) and emtricitabine (FTC) was the most common (81%) among NRTI associated mutations followed by K65R (34.5%) which is associated with both tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide fumarate (TAF) resistance.
Result: Of these (n = 45), 19 had the K65R mutation that confers resistance to tenofovir and abacavir but potentiates the effectiveness of zidovudine as a second line option.
Result: Overall, the 10 most common mutations were M184V (81%), K103N (65.5%), Y188C (36.2%), Y181C (36.2%), V106A (36.2),
Impact of archived M184V/I mutation on the effectiveness of switch to co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide among virally suppressed people living with HIV.
PMID: 32737511
2020
The Journal of antimicrobial chemotherapy
Abstract: RESULTS: Overall, 100 case patients with the M184V/I mutation were identified, including 6 (6.0%) with K65R and 13 (13.0%) with at least one TAM, and were matched to 400 controls in terms of gender, age (mean = 40.3 versus 39.7 years) and cumulative exposure duration to tenofovir disoproxil fumarate (median = 146 versus 143 weeks).
Abstract: The presence of the K65R mutation or TAMs was not associated with virological non-response.
Transmitted drug resistance mutations and subtype diversity amongst HIV-1 sero-positive voluntary blood donors in Accra, Ghana.
Abstract: CONCLUSION: This study found major drug resistance mutations, E138A and K65R in the RT gene that confer high level resistance to most NNRTIs and NRTI respectively.
Abstract: Nucleotide sequencing of amplified samples revealed the presence of major drug resistance mutations in two (2) samples; E138A in one sample and another with K65R.
Discussion: The K65R mutation is found to reduce viral susceptibility to most NRTIs by approximately 2-fold and rather increase susceptibility to AZT and hence reduced viral replication with zidovudine-containing therapy.
Discussion: Two (2) major DRMs were found in two (2) samples sequenced in the
High Levels of Acquired HIV Drug Resistance Following Virological Nonsuppression in HIV-Infected Women from a High-Risk Cohort in Uganda.
PMID: 32475121
2020
AIDS research and human retroviruses
Abstract: The mutation K103N was detected in 62.5% (30/48) of participants, 41.7% (20/48) had M184V/I, 14.6% had K65R, and 12.5% (6/48) had thymidine analog mutations (TAMs).
HIV-1 Genetic Diversity and High Prevalence of Pretreatment Drug Resistance in Tianjin, China.
PMID: 32539490
2020
AIDS research and human retroviruses
Abstract: The most frequent mutation pattern against NNRTIs was V179D/E/T (6.9%, 21/305), with M184V (1.0%, 3/305) and K65R (1.0%, 3/305) against nucleoside RT inhibitors (NRTIs).
Diagnostic Accuracy of Pan-Degenerate Amplification and Adaptation Assay for HIV-1 Drug Resistance Mutation Analysis in Low- and Middle-Income Countries.
PMID: 32522826
2020
Journal of clinical microbiology
Abstract: In a cross-sectional study (June 2018 to September 2019), we evaluated the diagnostic accuracy of a simple and rapid HIVDR assay (the pan-degenerate amplification and adaptation [PANDAA] assay targeting the mutations K65R, K103NS, M184VI, Y181C, and G190A) compared to Sanger sequencing and next-generation sequencing (NGS).
Abstract: PANDAA showed strong agreement with Sanger sequencing for K65R, K103NS, M184VI, and G190A (kappa > 0.85) and substantial agreement for Y181C (kappa = 0.720).
HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance.
Introduction: Patients failing an NNRTI-based first-line regimen with genotypic drug resistance mutations typically present with M184V/I, K65R, and/or thymidine analogue mutations (TAMs) and K103N, V106M/A and/or Y181C as the most prevalent NRTI and NNRTI mutations, respectively.
Table: K65R
Discussion: Secondly, only a limited number of TDF-treated patients were included in this study and in light of the high prevalence of the K65R mutation in sub-Saharan African countries, it is unclear whether our conclusions are applicable to patients re-suppressing or failing TDF-based regimens in this setting.
HIV mutation literature information.
PMID: 
2020
SAGE open medicine
Browser Board
Co-occurred Entities
Filtrator
ViMRT